Background: Eating disorders (ED) are a diagnostic category that includes several nosological units such as anorexia nervosa (AN), bulimia nervosa (BN), or binge eating disorder (BED). This category most often concerns women, while the peak incidence falls on the reproductive age. Therefore the issue of ED during pregnancy is an interesting topic. Due to the creation of unrealistic ideal of “desired,” slim figure both by the mass media and social media even during and right after gestation, more and more pregnant women introduce behaviours aimed at maintaining the “perfect” appearance. However in some cases it may have serious consequences for the health of both mother and child leading to the creation of the term “pregorexia” by the media to describe this issue.Aim: The aim of this paper was to conduct a systematic review of the literature dealing with eating disorders in pregnant women, with particular emphasis on pregorexia.Method: A systematic review of literature published within the last 5 years (2016–2021) in English or Polish and available through MEDLINE / PubMed, Google Scholar and Cochrane Library databases was conducted based on the previously assumed inclusion and exclusion criteria.Results: Initially, 634 publications were obtained during the review, of which 55 papers were selected in the course of the title analysis. After further evaluation of abstracts, 28 papers were qualified for full text analysis. Ultimately, 10 papers were selected for the final analysis.Conclusions: The issue of ED in pregnant women is a broad topic covering a heterogeneous group of women—both those with a previous history and those with the onset during pregnancy. The occurrence of ED symptoms during this period is associated with a high likelihood of negative consequences for both the mother and the child. The course of pregnancies and deliveries in these patients is more complicated. Therefore, it seems reasonable to develop a multidisciplinary screening strategy and standards of management and supervision over this group of patients.
Cel pracyCelem badania była ocena stężeń wybranych neuropeptydów : feniksyny, speksyny oraz kisspeptyny w surowicy krwi żylnej dzieci i młodzieży z choroba afektywną dwubiegunową, a tym samym ich skuteczności predykcyjnej w tym zaburzeniu.MetodaMateriał i metoda. Badanie objęło 75 osób w wieku średnio 15,26 lat (95%CI: 14.86-15.67 ), z czego grupę badaną stanowiło 57 osób z diagnozą choroby afektywnej dwubiegunowej, a grupę kontrolną - 18 osób bez diagnozy psychiatrycznej i nieleczonych farmakologicznie. Feniksynę, speksynę i kisspeptynę oznaczano w surowicy krwi z żyły obwodowej. Pomiary stężeń neuropeptydów wykonano metodą immunoenzymatyczną ELISA.WynikiŚrednie stężenie feniksyny w grupie badanej wynosiło 1,57 ng/ml (95%CI: 1,35-1,79), natomiast w grupie kontrolnej – 2,69 ng/ml (95%CI: 2,38-3; U Mann-Whitney test p-value<0,05). W przypadku speksyny wyniki te wynosiły odpowiednio: 639,65 pg/ml (95%CI: 558,86-720,44) w grupie badanej oraz 354,28 pg/ml (95%CI: 310,33-398,22; U Mann-Whitney test p-value<0,05) w grupie kontrolnej. Obserwowane różnice były istotne statystycznie. W zakresie poziomu kisspeptyny średnie stężenie w grupie badanej wynosiło 126,02 pg/ml (95%CI: 39,82-212,23; mediana: 59,85), zaś w grupie kontrolnej - 54,83 pg/ml (95%CI: 39,23-70,43; mediana: 51,3; U Mann-Whitney test p-value=0,29), a obserwowana różnica nie była istotna statystycznie.WnioskiWystępowanie objawów choroby afektywnej dwubiegunowej jest w istotny statystycznie sposób powiązane z obniżonym stężeniem PNX oraz w niewielkim stopniu z podwyższonym stężeniem speksyny w surowicy krwi chorych. Nie wykazuje natomiast związku ze stężeniem kisspeptyny.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.